Bioimpedance analysis combined with sagittal abdominal diameter for abdominal subcutaneous fat measurement.

Abdominal subcutaneous fat tissue (ASFT) is an independent predictor of mortality. This prospective observational study aimed to establish a rapid, safe, and convenient estimation equation for abdominal subcutaneous fat area (SFA) using bioimpedance analysis (BIA) combined with sagittal abdominal diameter (SAD). A total of 520 adult subjects were recruited and were randomly divided into 2/3 (n = 346) and 1/3 (n = 174) to form a modeling group (MG) and a validation group (VG), respectively. Each subject's abdomen was scanned using computed tomography to obtain target variables (SFACT). Predictor variables for all subjects included bioimpedance index (h2/Z), anthropometric parameters height (h), weight (W), waist circumference (WC), hip circumference (HC), and SAD, along with age and sex (male =1, female = 0). SFA estimation equation SFABIA+SAD was established for the MG using stepwise multiple regression analysis. Cross-validation was performed using VG to evaluate the performance of the SFABIA+SAD estimation equation. Stepwise multiple regression analysis was applied from the MG, including SFABIA+SAD = 49.89 + 1.09 SAD-29.90 Sex + 4.71 W-3.63 h2/Z-1.50 h (r = 0.92, SEE = 28.10 cm2, n = 346, p < 0.001). Mean differences in SFABIA+SAD relative to SFACT were -1.21 ± 21.53, 2.85 ± 27.16, and -0.98 ± 36.6 cm2 at different levels of obesity (eutrophic, overweight, obese), respectively. This study did not have a large number of samples in different fields, so it did not have completely external validity. Application of BIA combined with SAD in anthropometric parameters achieves fast, accurate and convenient SAF measurement. Results of this study provide a simple, reliable, and practical measurement that can be widely used in epidemiological studies and in measuring individual SFA.

Synergistic Antitumor Effect of Oligogalacturonides and Cisplatin on Human Lung Cancer A549 Cells.

Cisplatin (DPP), a clinically potent antineoplastic agent, is limited by its severe adverse effects. The aim of this study was to investigate the effect of oligogalacturonides (OGA) and DDP on human lung cancer A549 cells. The combined use of OGA and DDP had a synergistic effect on the growth inhibition of A549 cells, changed the cell cycle distribution, and enhanced apoptotic response, especially in sequential combination treatment group of DDP 12 h + OGA 12 h. Western blot analyses showed that the combination treatment of OGA and DDP upregulated Bax, p53, and Caspase-3 and downregulated Bcl-2 proteins. More importantly, DDP-induced toxicity was attenuated by OGA and DDP combination treatment in normal HEK293 cells. Our data suggests that the combined use of OGA from natural sources and DDP could be an important new adjuvant therapy for lung cancer as well as offer important insights for reducing kidney toxicity of DDP and delaying the development of DDP resistance.

Discrepancies between leg-to-leg bioelectrical Impedance analysis and computerized tomography in abdominal visceral fat measurement.

The aim of this study was to evaluate leg-to-leg bioelectrical impedance analysis (LBIA) using a four-contact electrode system for measuring abdominal visceral fat area (VFA). The present study recruited 381 (240 male and 141 female) Chinese participants to compare VFA measurements estimated by a standing LBIA system (VFALBIA) with computerized tomography (CT) scanned at the L4-L5 vertebrae (VFACT). The total mean body mass index (BMI) was 24.7 ± 4.2 kg/m2. Correlation analysis, regression analysis, Bland-Altman plot, and paired sample t-tests were used to analyze the accuracy of the VFALBIA. For the total subjects, the regression line was VFALBIA = 0.698 VFACT + 29.521, (correlation coefficient (r) = 0.789, standard estimate of error (SEE) = 24.470 cm2, p < 0.001), Lin's correlation coefficient (CCC) was 0.785; and the limit of agreement (LOA; mean difference ±2 standard deviation) ranged from -43.950 to 67.951 cm2, LOA% (given as a percentage of mean value measured by the CT) was 48.2%. VFALBIA and VFACT showed significant difference (p < 0.001). Collectively, the current study indicates that LBIA has limited potential to accurately estimate visceral fat in a clinical setting.

Cross-mode bioelectrical impedance analysis in a standing position for estimating fat-free mass validated against dual-energy x-ray absorptiometry.

Bioelectrical impedance analysis (BIA) is commonly used to assess body composition. Cross-mode (left hand to right foot, Z(CR)) BIA presumably uses the longest current path in the human body, which may generate better results when estimating fat-free mass (FFM). We compared the cross-mode with the hand-to-foot mode (right hand to right foot, Z(HF)) using dual-energy x-ray absorptiometry (DXA) as the reference. We hypothesized that when comparing anthropometric parameters using stepwise regression analysis, the impedance value from the cross-mode analysis would have better prediction accuracy than that from the hand-to-foot mode analysis. We studied 264 men and 232 women (mean ages, 32.19 ± 14.95 and 34.51 ± 14.96 years, respectively; mean body mass indexes, 24.54 ± 3.74 and 23.44 ± 4.61 kg/m2, respectively). The DXA-measured FFMs in men and women were 58.85 ± 8.15 and 40.48 ± 5.64 kg, respectively. Multiple stepwise linear regression analyses were performed to construct sex-specific FFM equations. The correlations of FFM measured by DXA vs. FFM from hand-to-foot mode and estimated FFM by cross-mode were 0.85 and 0.86 in women, with standard errors of estimate of 2.96 and 2.92 kg, respectively. In men, they were 0.91 and 0.91, with standard errors of the estimates of 3.34 and 3.48 kg, respectively. Bland-Altman plots showed limits of agreement of -6.78 to 6.78 kg for FFM from hand-to-foot mode and -7.06 to 7.06 kg for estimated FFM by cross-mode for men, and -5.91 to 5.91 and -5.84 to 5.84 kg, respectively, for women. Paired t tests showed no significant differences between the 2 modes (P > .05). Hence, cross-mode BIA appears to represent a reasonable and practical application for assessing FFM in Chinese populations.

Predicting body composition using foot-to-foot bioelectrical impedance analysis in healthy Asian individuals.

BACKGROUND: The objectives of this study were to develop a regression model for predicting fat-free mass (FFM) in a population of healthy Taiwanese individuals using standing foot-to-foot bioelectrical impedance analysis (BIA) and to test the model's performance in predicting FFM with different body fat percentages (BF%). METHODS: We used dual-energy X-ray absorptiometry (DXA) to measure the FFM of 554 healthy Asian subjects (age, 16-75 y; body mass index, 15.8-43.1 kg/m(2)). We also evaluated the validity of the developed multivariate model using a double cross-validation technique and assessed the accuracy of the model in an all-subjects sample and subgroup samples with different body fat levels. RESULTS: Predictors in the all-subjects multivariate model included height(2)/impedance, weight, year, and sex (FFM = 13.055 + 0.204 weight + 0.394 height(2)/Impedance - 0.136 age + 8.125 sex (sex: Female = 0, Male = 1), r(2) = 0.92, standard error of the estimate = 3.17 kg). The correlation coefficients between predictive FFM by BIA (FFMBIA) and DXA-measured FFM (FFMDXA) in female subjects with a total-subjects BF%DXA of <20 %, 20 %-30 %, 30 %-40 % and >40 % were r = 0.87, 0.90, 0.91, 0.89, and 0.94, respectively, with bias ± 2SD of 0.0 ± 3.0 kg, -2.6 ± 1.7 kg, -1.5 ± 2.8 kg, 0.5 ± 2.7 kg, and 2.0 ± 2.9 kg, respectively. The correlation coefficients between FFMBIA and FFMDXA in male subjects with a total-subjects BF%DXA of <10 %, 10 %-20 %, 20 %-30 %, and >30 % were r = 0.89, 0.89, 0.90, 0.93, and 0.91, respectively, with bias ± 2SD of 0.0 ± 3.2 kg, -2.3 ± 2.5 kg, -0.5 ± 3.2 kg, 0.4 ± 3.1 kg, and 2.1 ± 3.2 kg, respectively. CONCLUSIONS: The standing foot-to-foot BIA method developed in this study can accurately predict FFM in healthy Asian individuals with different levels of body fat.

Comparative proteomic profiles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation.

Familial aggregation of hepatocellular carcinoma (HCC), the third leading cause of cancer death worldwide, has shown to be a common phenomenon. We investigated the association between the genetic background and HCC familial aggregation. Serum samples were collected from HCC family members and normal control family members for screening the differentially expressed protein peaks with the approach of surface-enhanced laser desorption ionization time-of-flight mass spectrometry. Potential genetically associated protein peaks were selected and further identified by matrix assisted laser desorption ionization-time of flight mass spectrometry. A panel of six protein peaks (m/z 6432.94, 8478.35, 9381.91, 17284.67, 17418.34, and 18111.04) were speculated to reflect the genetic susceptibility of HCC familial aggregation. Three of them (m/z 6432.94, 8478.35, and 9381.91) were selected to identify as the candidate proteins. Nine identified proteins, including mostly apolipoprotein family (ApoA1, ApoA2, ApoC3, ApoE) and serum amyloid A protein (SAA), were found overexpressed in the multiple HCC cases family members. The comparative proteomic profiles have suggested that genetic factors ought to be taken into account for familial aggregation of HCC.

[Clinicopathologic correlation between CD4-positive T lymphocyte counts and superficial lymphadenopathy in HIV-positive/AIDS patients].

OBJECTIVE: To explore the clinicopathological correlation between CD4(+) T lymphocyte count and superficial lymphadenopathy HIV/AIDS patients. METHODS: A total of 1066 HIV/AIDS patients were included in this study. The incidence of superficial lymphadenopathy, peripheral blood CD4(+) T lymphocyte counts and histological features of superficial lymphadenopathy were analyzed. RESULTS: Among 1066 patients, 126 cases (11.8%) presented with superficial lymphadenopathy. Of the 126 cases, there were 69 cases with CD4(+) T lymphocyte counts < 100/µl and clinical diagnoses including tuberculosis (37 cases), reactive hyperplasia (8 cases), AIDS-related lymphadenopathy (18 cases), penicillium diseases (12 cases), fungal infection (5 cases) and non-tuberculous mycobacterial infection (1 case). Twenty-six cases had CD4(+) T lymphocyte counts between 100/µl to 200/µl and clinical diagnosis including tuberculosis (12 cases), reactive hyperplasia (8 cases), AIDS-related lymphadenopathy(6 cases), penicillium disease (2 cases) and non-Hodgkin lymphoma (1 case). Twenty-nine cases had CD4(+) T lymphocyte counts > 200/µl and clinical diagnoses including tuberculosis (11 cases), reactive hyperplasia (12 cases), AIDS-related lymphadenopathy (3 cases), Penicillium diseases (1 case) and non-Hodgkin lymphoma (4 cases). The CD4(+) T lymphocyte counts among patients with tuberculosis, AIDS-related lymphadenopathy and Penicillium diseases were significantly different (χ(2) = 8.861, P = 0.012). A significant correlation between the incidence of superficial lymphadenopathy and CD4(+) T lymphocyte counts was found (χ(2) = 375.41, P = 0.000). CONCLUSIONS: The most common cause of superficial lymphadenopathy in HIV/AIDS patients is tuberculosis, followed by lymph node reactive hyperplasia, AIDS-related lymphadenopathy and Penicillium disease. Low CD4(+) T lymphocyte count correlates with an increased incidence of superficial lymphadenopathy and the risk of opportunity infection. Therefore, determination of peripheral blood CD4(+) T lymphocyte count should become an integral marker for the early diagnosis and treatment of superficial lymphadenopathy in HIV/AIDS patients.

Caffeic acid phenethyl ester, an antioxidant from propolis, protects peripheral blood mononuclear cells of competitive cyclists against hyperthermal stress.

Hyperthermal stress and resulting free radical generation is known to impair endurance capacity and immune cell redistribution during prolonged exercise. Caffeic acid phenethyl ester (CAPE), a phenolic compound purified from propolis, has many biological and pharmacological activities including antioxidation. To examine whether CAPE has protective effect against hyperthermal stress in athletes, we isolated peripheral blood mononuclear cells (MNC) from competitive cyclists and assessed their response to hyperthermia with or without CAPE pretreatment. We found that pretreatment of cyclists' MNC with CAPE (0, 1, 2, 4 microg/mL) reversed or reduced hyperthermia-induced survival inhibition, necrosis, superoxide production, glutathione depletion, and intracellular superoxide burst in a dose-dependent manner. These results suggest that CAPE may enhance the hyperthermal tolerance in immune mononuclear cells of competitive cyclists.

Identification and characterization of LDL receptor gene mutations in hyperlipidemic Chinese.

DNA screening for LDL receptor mutations was performed in 170 unrelated hyperlipidemic Chinese patients and two clinically diagnosed familial hypercholesterolemia patients. Two deletions (Del e3-5 and Del e6-8), eight point mutations (W-18X, D69N, R94H, E207K, C308Y, I402T, A410T, and A696G), and two polymorphisms (A370T and I602V) were identified. Of these mutations, C308Y and Del e6-8 were found in homozygosity, and D69N and C308Y were seen in unrelated patients. The effects of mutations on LDL receptor function were characterized in COS-7 cells. The LDL receptor level and activity were close to those of wild type in A696G transfected cells. A novel intermediate protein and reduction of LDL receptor activity were seen in D69N transfected cells. For R94H, E207K, C308Y, I402T, and A410T mutations, only approximately 20-64% of normal receptor activities were seen. Conversely, Del e3-5 and Del e6-8 lead to defective proteins with approximately 0-13% activity. Most of the mutant receptors were localized intracellularly, with a staining pattern resembling that of the endoplasmic reticulum and Golgi apparatus (D69N, R94H, E207K, C308Y, and I402T) or endosome/lysosome (A410T and Del e6-8). Molecular analysis of the LDL receptor gene will clearly identify the cause of the patient's hyperlipidemia and allow appropriate early treatment as well as antenatal and family studies.